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ABSTRACT
Objectives: To systematically review the literature
pertaining to the prevalence of depression and anxiety
in patients with prostate cancer as a function of
treatment stage.
Design: Systematic review and meta-analysis.
Participants: 4494 patients with prostate cancer from
primary research investigations.
Primary outcome measure: The prevalence of
clinical depression and anxiety in patients with prostate
cancer as a function of treatment stage.
Results: We identified 27 full journal articles that met
the inclusion criteria for entry into the meta-analysis
resulting in a pooled sample size of 4494 patients. The
meta-analysis of prevalence rates identified
pretreatment, on-treatment and post-treatment
depression prevalences of 17.27% (95% CI 15.06% to
19.72%), 14.70% (95% CI 11.92% to 17.99%) and
18.44% (95% CI 15.18% to 22.22%), respectively.
Pretreatment, on-treatment and post-treatment anxiety
prevalences were 27.04% (95% CI 24.26% to
30.01%), 15.09% (95% CI 12.15% to 18.60%) and
18.49% (95% CI 13.81% to 24.31%), respectively.
Conclusions: Our findings suggest that the
prevalence of depression and anxiety in men with
prostate cancer, across the treatment spectrum, is
relatively high. In light of the growing emphasis placed
on cancer survivorship, we consider that further
research within this area is warranted to ensure that
psychological distress in patients with prostate cancer
is not underdiagnosed and undertreated.
INTRODUCTION
Prostate cancer (PCa) represents the most
common form of non-cutaneous malignancy
diagnosed in British men.1 Over 36 000 new
cases were diagnosed in 2007, accounting for
almost 25% of the total yearly number of
male cancer diagnoses.1 With an ageing UK
population and increasing utilisation of PCa
screening in asymptomatic men,2 the inci-
dence rates of PCa are predicted to continue
increasing year on year.1
In light of such a substantial and sustained
disease burden, the management of
survivorship issues within PCa assumes para-
mount importance. Such issues revolve
around the effective maintenance of quality
of life (QoL) throughout the cancer journey,
from initial diagnosis through to post-
treatment survivorship. In addition, the
National Cancer Survivorship Initiative
(NCSI) established ﬁve key goals of improved,
personalised and patient-centred care in the
UK.3 One goal was the need to better address
the speciﬁc psychological concerns associated
with the diagnosis and treatment of cancer.
Depression and anxiety are two of the
most commonly experienced psychological
conditions experienced by patients with
cancer4 and are associated with unique psy-
chophysiological side effects that importantly
encompass poorer treatment outcomes,5
increased periods of hospitalisation6 and
higher mortality rates.7 With the advances in
treatment efﬁcacy, cancer is being increas-
ingly viewed and treated as a chronic disease
that can be effectively managed for many
years. Given the longevity associated with the
trajectory of PCa (over 70% of patients with
PCa can expect to live for 10 years or more
from the time of diagnosis), it is possible that
the onset of psychological distress within this
population of men is not an acute threat that
passes quickly but a chronic one with peaks
and troughs of severity that occur at key
stages of the cancer journey.
Strengths and limitations of this study
▪ This is the first meta-analysis to define depres-
sion and anxiety prevalence specifically within
prostate cancer.
▪ Limited data are available for patients on active
surveillance and with metastatic disease.
▪ Cross-sectional methodologies make it difficult
to draw definitive conclusions about the history
and progression of anxiety and depression over
the cancer journey in this population.
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The research base evaluating the prevalence of depres-
sion and anxiety within PCa is growing steadily and a
sizeable body of clinically relevant research exists cur-
rently. Unfortunately, much of the data is very heteroge-
neous and of poor methodological quality and has yet to
be subjected to rigorous systematic review and
meta-analysis. This lack of synthesis makes it very difﬁ-
cult for physicians and allied healthcare professionals
working with PCa to access, interpret and apply the key
research ﬁndings to their clinical practice.
It is as yet unclear what stages of the PCa cancer
journey patients ﬁnd most distressing. Were this known,
or at least better understood, it would allow healthcare
professionals to be more proactive and aware of what
stages of treatment patients are most likely to experience
depression and anxiety. This would allow healthcare
teams to risk adapting their psychological screening and
support processes.
The current meta-analysis was undertaken to address
this issue and provide an initial baseline estimate of the
prevalence of clinical depression and anxiety in patients
with PCa during each of the three key stages of cancer
treatment: pretreatment, on-treatment and
post-treatment.
METHOD
Eligibility criteria
Studies that investigated the speciﬁc prevalence of
depression and anxiety in patients with PCa in full
journal articles were included. Studies published in con-
ference proceedings, qualitative research, commentaries
and discussions, letters, books, book chapters or
research not published in the English language were
excluded.
Eligible studies were restricted to research focusing on
individuals with a biopsy conﬁrmed diagnosis of PCa. If
patients with PCa were included within an investigation
that recruited mixed cancer populations, the study was
required to have reported data about the patients with
PCa as a distinct subsample. The primary outcome for
the current meta-analysis was the prevalence of depres-
sion and anxiety. Thus, inclusion into the meta-analysis
was restricted to those studies that reported PCa-speciﬁc
prevalence data for depression and anxiety separately.
To be eligible for inclusion, each study was required to
provide a clear deﬁnition of the PCa treatments under-
taken by the study participants and when such treat-
ments took place (ie, treatment that was yet to be
undertaken, was being undertaken at the time of the
study or had already been completed. For the latter cat-
egory, it was a requirement that the authors speciﬁed
the time lapse since the cessation of treatment).
Questionnaire analysis
Entry into the meta-analysis was also restricted to data
that were collected from questionnaires that provided
speciﬁc, valid and reliable measurements of depression
and anxiety. To enable this, a series of questionnaire spe-
ciﬁc inclusion criteria were created against which all of
the questionnaires utilised in the studies could be
assessed; each questionnaire must:
Allow for the speciﬁc and independent measurement
of depression and anxiety;
Have available established threshold information (mea-
surements) for the diagnosis of depression and
anxiety;
The validity of each questionnaire must have been
assessed in comparison to established ‘gold standard’
questionnaires;
The internal validity and reliability of each question-
naire must have been assessed and deemed acceptable
(test–retest).
Twelve questionnaires meeting the criteria were identi-
ﬁed which included the Hospital Anxiety and Depression
Scale, Stait-Trait Anxiety Scale, Centre for Epidemiologic
Studies Depression Scale, Symptom Checklist, Beck
Depression Inventory, Self-Rating Anxiety Scale,
Self-Rating Depression Scale, Brief Symptom Inventory,
Composite International Diagnostic Interview, Memorial
Anxiety Scale for Prostate Cancer and the Effects of
Prostate Cancer on Lifestyle Questionnaire.
Identifying research evidence
Data searches were conducted between June and August
2011. The search protocol was subsequently rerun in
June 2013 to ensure that no additional data were identi-
ﬁed. We searched six electronic databases (OVID
MEDLINE, EMBASE, AMED, PsycINFO, CINAHL and
Web of Science) for articles that met the previously dis-
cussed criteria using prespeciﬁed MESH terms that
included Prostate Neoplasm (EXP)’ OR ‘Prostate
Cancer’ AND ‘Depression (EXP)’ or ‘Anxiety (EXP)’ or
‘Psychological distress (EXP’ or ‘Stress (EXP)’ or
‘Distress (EXP)’. No restrictions on publication dates
were imposed.
To supplement the electronic searches, we also con-
ducted searches of the reference lists of previous
reviews, key papers and other relevant articles identiﬁed
by the electronic search. We also conducted systematic
searches of the content lists of key journals to identify
any additional studies missed by the electronic search.
Study selection
Titles and abstracts were initially assessed for eligibility. If
it was possible to conﬁrm that an article met the inclu-
sion criteria from the abstract alone, the full text article
was retrieved. If it was clear from the abstract that an
article was not eligible, it was rejected immediately. If it
was not possible to determine the eligibility of an article
from the abstract, the full text article was retrieved.
If any key information was missing, we contacted the
authors for the missing data. If this was not possible or
ineffective, the study was rejected, (see ﬁgure 1).
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Data extraction
The following speciﬁc information relating to data collec-
tion and results was extracted individually from each iden-
tiﬁed article and entered into a predesigned Excel
spreadsheet: date and geographical location of data collec-
tion; aims and objectives of the investigation; study design;
participant inclusion and exclusion criteria; recruitment
procedures; sample size; disease stage; sociodemographic
status (age, ethnicity and relationship, educational and
employment status); time since diagnosis; additional
comorbidity; stage of treatment (pretreatment,
on-treatment or post-treatment); treatments undertaken
(surgery, radiotherapy, hormone therapy, chemotherapy,
active surveillance (AS)/watchful waiting (WW)); ques-
tionnaires utilised; statistical analyses performed; depres-
sion prevalence (%) and anxiety prevalence (%).
To test the consistency of data extraction across the
studies, three researchers (SW, LL, SE) extracted data
from the same six randomly selected articles, then com-
pared the results of their extraction. A points system was
utilised to allow for the objective assessment of consist-
ency. One point was allocated for variables with identical
data extraction and 0 points for variables with differ-
ences. Across all ratings, consistency ranged from 92%
to 96% (median: 94%).
Meta-analysis procedure
Given the range of the estimated proportions expected
within the extracted data, the logits of proportions
method of conducting the statistical analysis was
employed, rather than one utilising normal approxima-
tions of binomial distributions.
Cochran’s Q test was applied to the logits to test the
hypothesis of homogeneity of the within-study estimates
of the proportions, with larger Q values suggesting that
the estimates are not homogeneous. Initial analyses
highlighted Q values between Q=15.2 and 215, with
some of the larger values suggesting a degree of hetero-
geneity, the result in some cases of only one or two
studies being out of line with the others. For complete-
ness, meta-analysis results have been provided even for
those cases where heterogeneity is evident.
RESULTS
Search results
The electronic database searches initially yielded 1778
journal article references. Of these, 1655 were subse-
quently removed due to either duplication or a failure
to meet the inclusion criteria. Full text articles were
then retrieved and critically appraised for the remaining
Figure 1 PRISMA flow diagram.
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123 journal references. Of these 123 articles, 97 did not
meet the inclusion criteria. The remaining 26 articles
were entered into the meta-analysis.
Hand searches of the key journals identiﬁed by the
electronic database search revealed no additional
journal articles. Searching the reference lists of articles
identiﬁed through the electronic database search identi-
ﬁed two journal article references of interest that had
otherwise been missed. Full text articles were retrieved
for both of these references, one of which was subse-
quently entered into the current review, making the
total number of included studies 27 (ﬁgure 1).
Study locations
Of the 27 studies entered into the review, 9 were con-
ducted within America,6–15 4 in Australia16–19 and
Holland,20–23 3 in the UK,24–26 2 each in Sweden,27 28
Germany29 30 and Canada31 32 and 1 in Finland.33 An
overview of the key features of each of the included
studies can be seen in table 1.
Study sample sizes
The sample sizes of the studies entered into the review
varied widely from 36 to 861. The total sample size
across all 27 studies was 4494 with a mean sample size of
158. The sample sizes of the individual treatment stage
groups (pretreatment, on-treatment and post-treatment)
can be seen in table 2.
Participant age
Data on participant age was reported by 24 of the 27
studies, and in all 24 cases, mean age was reported. The
range of mean ages across the 24 studies varied from
57.5 to 73.2 years. The mean age of all participants
across the 24 studies was 66.3 years (3.3). Three studies
failed to report participant age in any format. The mean
age of the participants in each of the three treatment
groups can be seen in table 2.
Cancer staging
Data regarding participant cancer stage were reported
by 23 of the 27 studies. There was a general lack of con-
sistency regarding reporting methods. Several studies uti-
lised the clinical T-staging system of T1 (localised) to T4
Table 1 Key features of the included studies
Author Year Location
Sample
size
Participant
age Cancer stage Treatment stage
Ene 2006 Sweden 123 63.1 No data provided Pretreatment to Post-treatment
Pirl 2008 USA 50 62 Advanced Pre and On-treatment
Sharpley 2007 Australia 195 69.2 Localised Post-treatment
Bisson 2002 Wales 83 64.5 Mixed Pretreatment
Dirkson 2009 USA 51 73.4 Mixed On-treatment
Dale 2009 USA 67 67.9 No data provided Pretreatment (but all participants
had received prior primary therapy)
Gabershagen 2007 Germany 115 64.1 Localised Pretreatment
Gabershagen 2009 Germany 84 62.8 Mixed Pretreatment to post-treatment
Hervouet 2005 Canada 861 67.9 Mixed Post-treatment
Monga 1999 USA 36 66 Localised Pretreatment to On-treatment to
Post-treatment
Monga 2005 USA 40 67.8 Localised Pretreatment to On-treatment to
Post-treatment
Pirl 2002 USA 45 69.4 Localised and
Metastatic
On-treatment
Savard 2005 Canada 327 66 localised Post-treatment
Stone 2000 England 62 69 Mixed On-treatment
Soloway 2004 USA 103 62 No data provided Pretreatment
Steineck 2002 Finland 326 64.5 Localised Post-treatment
Symon 2006 USA 50 59.9 Localised Pretreatment to Post-treatment
Sharpley 2007 Australia 183 69.2 Localised Post-treatment
Sharpley 2009 Australia 150 69.8 Localised Post-treatment
van Tol-Geerdink 2006 Holland 118 70 Localised Pretreatment
Van den Berg 2009 Holland 129 64.9 Localised On-treatment (active surveillance)
Van den Berg 2010 Holland 129 64.6 Localised On-treatment (active surveillance)
Monga 2001 USA 40 67.6 Localised Pretreatment to Post-treatment
Korfage 2006 Holland 299 65.4 Mixed Pretreatment Post-treatment
Bitsika 2009 Australia 381 No data Localised Post-treatment
Nordin 2001 Sweden 118 No data Localised & Advanced Pretreatment
Burnet 2007 England 329 68.8 Localised On-treatment and post-treatment
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(metastatic) while the majority simply graded PCa as
localised, advanced or metastatic. No study reported the
patient disease stage using the recommended
tumour-nodes-metastasis (TNM). The majority of
patients had been diagnosed with localised disease
(n=3270), followed by advanced (513) and metastatic
PCa (87), as shown in table 2.
Cancer treatments undertaken
Table 3 provides an overview of the number of partici-
pants undergoing each PCa treatment. Unfortunately, it
was not possible to stratify the treatments undertaken as
a function of either disease stage (localised, advanced or
metastatic) or treatment stage (on-treatment or post-
treatment). This was because in many instances patients
with different disease staging or who were at different
treatment stages were recruited into the same cohort.
Consequently, while the number of patients completing
each type of treatment was clearly highlighted, it was not
possible to determine whether the patients with loca-
lised, advanced or metastatic disease, or those who were
either currently undergoing treatment or had ﬁnished
treatment, had completed them. Thus, the data in table
3 provide a collective overview of the treatments under-
taken by all of the patients, irrespective of disease or
treatment stage. In addition, several of the pretreatment
studies recruited participants who had yet to decide on
treatment. Such patients are listed in table 3 as ‘newly
diagnosed’.
Questionnaires analysis
Of the 12 questionnaires meeting the questionnaire
inclusion criteria as listed in the method section, only 7
were utilised by the 27 studies entered into this
meta-analysis. Table 4 lists the seven questionnaires, the
frequency with which they were used and the clinical
cut-off scores utilised to determine caseness.
Meta-analysis of depression and anxiety prevalence
Number of studies reporting depression
Twenty-six of the 27 studies entered into the review
reported data on depression prevalence. Of these 26, 13
reported depression in pretreatment patients, 9 in
on-treatment patients and 13 in post-treatment patients.
The number of total studies from the 3 groups exceeded
27 as several longitudinal studies reported depression in
multiple treatment groups (ie, in pretreatment and
on-treatment groups).
Number of studies reporting anxiety
Twenty of the 26 studies entered into the review
reported data on anxiety prevalence. Of these 20, 9
reported anxiety in pretreatment patients, 4 in
on-treatment patients and 11 in post-treatment patients.
Number of patients measured for depression
Collectively, measures of depression were recorded from
5139 participants across the 26 studies. In terms of the
individual treatment groups, 1259 participants provided
measures of depression in the pretreatment group, 723
in the on-treatment group and 3157 in the post-
treatment group.
Number of patients measured for anxiety
Collectively, measures of anxiety were recorded from
4635 participants across the 20 studies. In terms of the
individual treatment groups, 1057 participants provided
measures of anxiety in the pretreatment group, 501 in
the on-treatment group and 3077 in the post-treatment
group.
Pretreatment depression and anxiety prevalence
Depression: within the 13 studies that provided measures
of depression in patients with PCa prior to undergoing
Table 2 Overview of study characteristics
All
studies
Pretreatment
studies
On-treatment
studies
Post-
treatment
studies
Study samples (patient numbers) 4494 1707 723 3087
Participant ages 66.3 (3.3) 64.8 (2.9) 67.6 (3.3) 66.9 (2.4)
Number of patients with localised PCa 3270 1299 563 2236
Number of patients with advanced PCa 513 162 72 441
Number of patients with metastatic PCa 87 58 40 7
PCa, prostate cancer.
Table 3 The number of prostate cancer patients being treated and undertaking each treatment modality
Radical
prostatectomy
Radiotherapy (EBRT
& brachytherapy)
Hormone Therapy
(orchiectomy and
ADT) Chemotherapy
Active surveillance
or watchful waiting
Newly diagnosed
(no treatment yet
selected)
924 1578 264 24 418 304
ADT, androgen deprivation therapy; EBRT, external beam radiotherapy.
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treatment (see ﬁgure 2), the prevalence of depression
was 17.27% (CI 15.06% to 19.72%).
Anxiety: Within the nine studies that provided mea-
sures of anxiety in patients with PCa prior to undergoing
treatment (see ﬁgure 2), the prevalence of anxiety was
27.04% (CI 24.26% to 30.01%).
On-treatment depression and anxiety prevalence
Depression: Within the nine studies that provided mea-
sures of depression in patients with PCa currently under-
going treatment (see ﬁgure 3), the prevalence of
depression was 14.70% (CI 11.92% to 17.99%).
Anxiety: within the four studies that provided mea-
sures of anxiety in patients with PCa currently undergo-
ing treatment (see ﬁgure 3), the prevalence of anxiety
was 15.09% (CI 12.15% to 18.60%).
Post-treatment depression and anxiety prevalence
Depression: within the 13 studies that provided measures
of depression in patients with PCa who had completed
treatment (see ﬁgure 4), the prevalence of depression
was 18.44% (CI 15.18% to 22.22%).
Anxiety: within the 11 studies that provided measures
of anxiety in patients with PCa who had completed treat-
ment (see ﬁgure 4), the prevalence of anxiety was
18.49% (CI 13.81% to 24.31%).
Depression and anxiety prevalence across and within
treatment groups
Figure 5 provides a pictorial representation of the preva-
lence of depression and anxiety both within and across
each of the three treatment groups.
DISCUSSION
There is a real need within clinical oncology, particularly
as the burden of disease is escalating with improved
diagnosis and treatment, for an increased awareness
about the issue of psychological distress among men
diagnosed with, being treated for and surviving
through/living with a PCa diagnosis. The results of the
current meta-analysis go some way in addressing this
issue by providing those working within the ﬁeld of PCa
with a rigorous overview of the likely prevalence of
depression and anxiety in the patients they treat.
Our ﬁndings suggest that over the trajectory of the
PCa journey, depression and anxiety prevalence are
highest in patients who have yet to undergo treatment
(17.27% and 27.4%, respectively), lowest in patients who
are currently undertaking treatment (14.70% and
15.90%, respectively) before rising again in patients who
have completed treatment (18.44% and 18.49%, respect-
ively). The relatively small variation observed within
these prevalence rates across the different treatment
stages, along with the large collective sample size of the
meta-analysis (4494), suggests that these conclusions are
valid, powerful and robust summaries of the data avail-
able. The prevalence of clinical depression and anxiety
in British men aged over 65 years is estimated to be less
than 9% and 6%, respectively.34 Such data are in stark
contrast to the prevalence reported in patients with PCa
of the same age in this study.
The current meta-analysis is the ﬁrst of its kind to spe-
ciﬁcally assess the prevalence of clinical depression and
anxiety in patients with PCa over their treatment spec-
trum, from pretreatment, through treatment to post-
treatment follow-up. Until now, the lack of synthesis of
the available data relating to depression and anxiety in
PCa has meant that clinical decisions have been based
Table 4 Questionnaires utilised, frequency of use and cut-off scores utilised
Questionnaire name Frequency of use Clinical cut-off scores utilised
Hospital anxiety and depression scale (HADS) 13 HADS-A: ≥8
HADS-D: ≥8
Beck depression inventory (BDI) 6 ≥10
Self rating anxiety scale (SAS) 4 ≥36
Self rating depression scale (SDS) 4 ≥40
Centre for epidemiologic studies depression scale (CES-D) 4 ≥15
Stait-Trait Anxiety Scale (STAI) 4 ≥44
Memorial anxiety scale for prostate cancer (MAX-PC) 3 ≥27
Figure 2 Pretreatment depression and anxiety %
prevalence.
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on isolated research trials that lack sufﬁcient power and
depth in terms of sample sizes, treatment protocols and
treatment stages. Consequently, the true prevalence of
psychological morbidity experienced by patients with
PCa across the treatment spectrum is poorly understood
and described and this may result in patients being left
untreated.
We hope that with additional epidemiological investi-
gation we will be able to offer a more risk adapted
approach with more intensive screening and support
being offered to individuals who are most at risk of psy-
chological morbidity, which may in part be related to
their current stage of treatment. This is important as
research suggests that patients with cancer who are suf-
fering from clinical depression and anxiety are less likely
to adhere to their treatment plan and are more likely to
experience adverse reactions to their treatment.4 5
Indeed, recently published research has speciﬁcally
highlighted the negative impacts of PCa speciﬁc anxiety
on post-treatment survivorship in the form of poorer
sexual function and increased depressive symptomology,
further supporting the need for effective and timely
intervention.35
Consequently, the identiﬁcation, treatment and man-
agement of concurrent psychological distress should be
a key clinical objective as a means of enhancing clinical
outcomes and patient QoL. Identifying which stage of
treatment patients with PCa are most likely to experi-
ence such conditions is an important ﬁrst step to achiev-
ing this.
There are several limitations to the results generated
by this review that need to be noted when interpreting
the ﬁndings. There is a noticeable dearth of research
into the prevalence of depression and anxiety in patients
with PCa with metastatic disease; we identiﬁed only 87
patients with metastatic PCa out of the pooled sample
size of 4494. Given the increased physical symptomology,
and signiﬁcantly lowered life expectancy, associated with
metastatic PCa, it is possible that the prevalence of psy-
chological morbidity within this patient cohort will prob-
ably be substantially higher. Unfortunately, it was not
possible to generate depression and anxiety prevalence
data speciﬁcally for men with metastatic disease, as the
studies that recruited patients with PCa with metastatic
disease did so as part of larger collective samples of
patients that included those with localised and/or
advanced PCa. In the majority of cases, no individual
depression and anxiety data were provided speciﬁcally
for those with metastatic disease. Consequently, it was
not possible to describe these patients separately.
We do not know the overall proportion of men who
suffer from some psychological distress during their PCa
cancer journey from these largely cross-sectional studies.
Figure 5 Depression and anxiety % prevalence across
treatments.
Figure 4 Post-treatment depression and anxiety %
prevalence.
Figure 3 On-treatment depression and anxiety %
prevalence.
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We suspect that a number of individuals become
depressed and anxious at various stages of their cancer
journey and then may improve, so overall the numbers
of people affected at some stage may be higher than we
are able to identify from this analysis. We would need to
conduct a sustained longitudinal cohort study to resolve
this question. Likewise, none of the included studies pro-
vided any form of data relating to the patients’ history of
depression and anxiety. Consequently, it was not possible
to determine whether a history of depression and
anxiety acted as a signiﬁcant predictor of current depres-
sion and anxiety.
Furthermore, this study did not compare the depres-
sion and anxiety prevalence rates generated directly to
that observed in a cohort to healthy men or men with
other cancers. As a consequence, we were unable to spe-
ciﬁcally determine how PCa and its treatment impacted
on the prevalence of psychological distress observed.
The essentially descriptive nature of this study therefore
needs to be noted.
It is also important to note the wide variability in the
point prevalence estimates of anxiety and depression
and the 95% CIs associated with them. There are likely
to be many reasons for this variability, which include
sample size, the differing instruments that have been
used to measure depression and anxiety, selective popu-
lations and post-treatment outcomes. For example, it is
possible that depression and anxiety prevalence in post-
prostatectomy patients would vary substantially depend-
ing on factors such as positive or negative margin status.
Unfortunately, it was not possible to formally investigate
the properties of the populations to determine whether
there were any such differences that would explain this
variability. This represents an important limitation to the
ﬁndings of this study. It is important that future studies
into the assessment of depression and anxiety in this
patient group carefully identify the characteristics of
their populations to address this issue.
We were also not able to determine whether the preva-
lence of depression and anxiety was a factor inﬂuencing
the type of PCa treatments provided to individuals. The
associated side effects of PCa treatment include debilitat-
ing urinary, sexual and bowel dysfunction as well as the
potentially negative psychological side effects of passive
treatment options such as AS and WW, in which the
patient faces living with a diagnosed but untreated
cancer. This is an important clinical issue as it may
provide a novel avenue in which to streamline the
screening of depression and anxiety by offering patients
undertaking treatments that have been shown to induce
higher rates of distress with early, preventive support
during their cancer journey.
Burnet et al27 reports that the prevalence of depres-
sion among AS/WW patients is just 4% (in a sample of
100 patients recruited from a single cancer centre of
international excellence), leading the authors to con-
clude that AS does not predispose patients to higher
levels of distress in comparison to those undergoing
radical treatment. However, our data identiﬁed that the
prevalence of depression is almost three times higher
than that reported by Burnet et al27 at 11% (within this
speciﬁc population, suggesting that psychological distress
may indeed be a substantial risk associated with AS/WW.
The utilisation and uptake of AS/WW within the UK
is increasing,36 yet our results clearly highlight that the
issue of psychological morbidity among these patients
with PCa is poorly described and deﬁned, with only 4 of
the 27 studies entered into this review obtaining mea-
sures of depression and anxiety from this patient popula-
tion.21 22 26 33 Consequently, we suggest that patients
being treated with AS/WW should be investigated in
more detail to better understand the psychological rami-
ﬁcations of this form of management. Such research
should ideally involve the recruitment of larger sample
sizes (>200) from multiple sites to provide a more gener-
alisable estimate of psychological distress from this
patient cohort.
In conclusion, across the treatment spectrum, patients
with PCa appear to experience a moderate to high
degree of psychological morbidity ranging from 15% to
27%. Most acute prevalences of depression and anxiety
occur prior to and after the completion of treatment,
the consequences of which may go on to negatively
impact on treatment compliance,6 increased periods of
hospitalisation5 and overall functional QoL.37 Based on
our ﬁndings, we conclude that the assessment, diagnosis
and treatment of depression and anxiety should be a key
priority for any clinical oncology team working with PCa
to enable them to optimise their patients’ QoL and clin-
ical treatment outcomes.
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